BioCentury | Dec 21, 2020

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

Amid a changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier a commercial product and a candidate in Phase III testing. The 12-year-old biotech now sees more value...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

Amgen readies sotorasib for FDA  Amgen Inc. (NASDAQ:AMGN) said it plans to submit an NDA for its closely watched KRAS inhibitor sotorasib by year-end to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C...
BioCentury | Dec 1, 2020
Product Development

With new Phase III results in rare anemia, Agios moves toward first non-oncology submission

Agios’ most advanced program for a rare genetic disease has cleared the bar in the first of two Phase III trials, putting the company one step closer to gaining approval of its first non-oncology product....
BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Jun 13, 2020
Product Development

Additional durability data build confidence for gene editing, gene therapies in hemoglobinopathies

It’s all about durability for gene therapies and gene editing treatments in hemoglobinopathies, and new data suggest programs from partners CRISPR Therapeutics and Vertex as well as bluebird are on track to deliver. In addition...
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BioCentury | May 3, 2019
Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
Items per page:
1 - 10 of 34